Skip to Content

Generic Fotivda Availability

Fotivda is a brand name of tivozanib, approved by the FDA in the following formulation(s):

FOTIVDA (tivozanib hydrochloride - capsule;oral)

  • Manufacturer: AVEO PHARMS
    Approval date: March 10, 2021
    Strength(s): EQ 0.89MG BASE [RLD], EQ 1.34MG BASE [RLD]

Has a generic version of Fotivda been approved?

No. There is currently no therapeutically equivalent version of Fotivda available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Fotivda. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Quinoline derivatives and quinazoline derivatives having azolyl group
    Patent 6,821,987
    Issued: November 23, 2004
    Inventor(s): Kazuo; Kubo & Teruyuki; Sakai & Rika; Nagao & Yasunari; Fujiwara & Toshiyuki; Isoe & Kazumasa; Hasegawa
    Assignee(s): Kirin Beer Kabushiki Kaisha

    An object of the present invention is to provide compounds having potent antitumor activity. The compounds according to the present invention are compounds represented by formula (I) or pharmaceutically acceptable salts or solvates thereof: wherein X and Z represent CH or N; Y represents O or S; R1, R2, and R3 represent H, alkoxy or the like; R4 represents H; R5, R6, R7, and R8 represent H, halogen, alkoxy or the like; R9 and R10 represent H, alkyl or the like; and R11 represents optionally substituted azolyl.

    Patent expiration dates:

    • April 26, 2022
      ✓ 
      Patent use: A METHOD OF TREATING ADULTS WITH RELAPSED OR REFRACTORY ADVANCED RENAL CELL CARCINOMA FOLLOWING TWO OR MORE PRIOR SYSTEMIC THERAPIES BY INHIBITING THE ANGIOGENESIS OF BLOOD VESSELS WITH A VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITOR
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n′-(5-methyl-3-isoxazolyl)urea salt in crystalline form
    Patent 7,166,722
    Issued: January 23, 2007
    Inventor(s): Matsunaga; Naoki & Yoshida; Satoshi & Yoshino; Ayako & Nakajima; Tatsuo
    Assignee(s): Kirin Beer Kabushiki Kaisha

    The present invention provides a crystal of a pharmaceutically acceptable salt of N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N′-(5-methyl-3-isoxazolyl) urea. This crystal of salt is usable for the therapy of a disease selected from the group consisting of tumors, diabetic retinopathy, chronic rheumatism, psoriasis, atherosclerosis, Kaposi's sarcoma, and exudation type age-related maculopathy, and has characteristics suitable for applications of oral pharmaceutical preparations.

    Patent expiration dates:

    • November 16, 2023
      ✓ 
      Drug substance

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.